Fulcrum Therapeutics (FULC) Expected to Post Earnings on Tuesday

Fulcrum Therapeutics (NASDAQ:FULC) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.21) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 3, 2026 at 9:30 AM ET.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. On average, analysts expect Fulcrum Therapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Fulcrum Therapeutics Trading Down 1.7%

NASDAQ:FULC traded down $0.07 during mid-day trading on Tuesday, hitting $3.67. The company had a trading volume of 59,533 shares, compared to its average volume of 1,624,824. The business has a fifty day simple moving average of $4.21 and a 200-day simple moving average of $7.08. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74. The firm has a market capitalization of $244.21 million, a price-to-earnings ratio of -3.19 and a beta of 3.01.

Analysts Set New Price Targets

FULC has been the subject of several analyst reports. Citigroup downgraded Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. Leerink Partners lowered Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price target on the stock. in a research report on Tuesday, June 2nd. Piper Sandler lowered Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research report on Tuesday, June 2nd. HC Wainwright cut Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Tuesday, June 2nd. Finally, Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $8.20.

Insider Buying and Selling at Fulcrum Therapeutics

In related news, Director Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics stock in a transaction on Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the sale, the director owned 10,927 shares in the company, valued at approximately $39,883.55. The trade was a 62.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FULC. Quarry LP acquired a new position in Fulcrum Therapeutics during the 3rd quarter worth $35,000. Meeder Asset Management Inc. acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at about $39,000. Russell Investments Group Ltd. lifted its position in shares of Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Fulcrum Therapeutics during the fourth quarter worth about $75,000. Finally, Evergreen Capital Management LLC acquired a new position in Fulcrum Therapeutics in the second quarter worth about $114,000. 89.83% of the stock is currently owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.